MyFinsight
Home
Blog
About
In-process research and
development
$2,260K
(0.00%↑ Y/Y)
Operating lease
right-of-use assets net
$6K
(-99.59%↓ Y/Y)
Finance lease
right-of-use assets net
$3K
(-50.00%↓ Y/Y)
Cash and cash
equivalents
$761K
(-88.34%↓ Y/Y)
Prepaid expenses and
other current assets
$332K
(-52.09%↓ Y/Y)
Restricted cash security
deposit
$50K
(0.00%↑ Y/Y)
Total non-current
assets
$2,269K
(-45.40%↓ Y/Y)
Total current assets
$1,143K
(-84.27%↓ Y/Y)
Total assets
$3,412K
(-70.13%↓ Y/Y)
Total liabilities and
stockholders equity
$3,412K
(-70.13%↓ Y/Y)
Total stockholders
equity
$1,800K
(-76.55%↓ Y/Y)
Total liabilities
$1,612K
(-57.00%↓ Y/Y)
Accumulated deficit
-$214,034K
(-3.54%↓ Y/Y)
Additional paid-in capital
$215,833K
(0.67%↑ Y/Y)
Total current
liabilities
$1,350K
(-24.33%↓ Y/Y)
Total non-current
liabilities
$262K
(-86.67%↓ Y/Y)
Common stock par value
0.0001 per share,...
$1K
(0.00%↑ Y/Y)
Accounts payable
$845K
(405.99%↑ Y/Y)
Accrued expenses
$504K
(-36.60%↓ Y/Y)
Financing lease
liabilities current
$1K
(-80.00%↓ Y/Y)
Deferred tax liability
$257K
(0.00%↑ Y/Y)
Financing lease
liabilities net of current...
$5K
(-54.55%↓ Y/Y)
Back
Back
Balance Sheet
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)
source: myfinsight.com